SGLT-2抑制剂埃图格列净的合成研究进展

IF 1.8 3区化学 Q3 CHEMISTRY, ORGANIC

Synthetic Communications Pub Date : 2025-04-18 DOI:10.1080/00397911.2025.2452291

Xiaojie Hu , Yue Wang , Jicun Wang , Lu Zheng , Qingkun Wu

引用次数: 0

摘要

ertuglilozin是一种口服钠-葡萄糖共转运蛋白2 （SGLT-2）抑制剂，可作为成人糖尿病患者的治疗选择。本文概述了文献记载的埃图格列净的六种合成途径，并对每种途径进行了简要分析，为今后的合成工艺优化提供了宝贵的资源。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research progress on synthesis of SGLT-2 inhibitor ertugliflozin

Ertugliflozin, an orally administered sodium-glucose cotransporter 2 (SGLT-2) inhibitor, serves as a therapeutic option for adult patients with diabetes mellitus. This comprehensive review outlines six synthetic routes of Ertugliflozin as documented in the literature, offering a concise analysis of each route to serve as a valuable resource for future synthesis process optimization.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Synthetic Communications 化学-有机化学

CiteScore

4.40

自引率

4.80%

发文量

156

审稿时长

4.3 months

期刊介绍： Synthetic Communications presents communications describing new methods, reagents, and other synthetic work pertaining to organic chemistry with sufficient experimental detail to permit reported reactions to be repeated by a chemist reasonably skilled in the art. In addition, the Journal features short, focused review articles discussing topics within its remit of synthetic organic chemistry.